biote stock price target lowered to $5.92 from $6.99 at Jefferies

Investing.com - Jefferies has lowered its price target on biote Corp. (NASDAQ:BTMD) to $5.92 from $6.99 while maintaining a Buy rating on the stock. According to InvestingPro data, the company trades at a P/E of 6.57 and shows strong profitability with a gross margin of 71.27%.

The firm cited biote’s second-quarter performance, which "wasn’t great" according to its analysis. Nutraceutical strength helped offset softer procedure sales, with the company’s top-line missing expectations by 100 basis points. Despite these challenges, the company maintained revenue growth of 6.44% over the last twelve months.

Jefferies noted that benefits from CDSS and restructuring efforts are taking more time to materialize than expected, leading biote to lower its guidance. The firm characterized these challenges as "not out of the ordinary in a transition year."

Despite the reduced price target, Jefferies maintained its Buy rating, highlighting that progress is being made and that management "seems to have a good sense of how to turn volumes around and drive new practitioner growth."

The firm is monitoring for better timing clarity on the company’s turnaround efforts, noting that "growth is rarely linear."

In other recent news, Biote Corp reported its second-quarter earnings for 2025, surpassing earnings per share (EPS) expectations but falling short on revenue forecasts. The company achieved an EPS of $0.10, which was higher than the anticipated $0.08, representing a 25% positive surprise. However, the revenue was $48.9 million, slightly below the expected $49.76 million. These recent developments highlight a mixed performance, with the EPS beat offset by a revenue shortfall. Despite the positive earnings surprise, investor concerns were evident due to the revenue miss. There were no recent announcements regarding mergers or acquisitions. Additionally, there have been no recent analyst upgrades or downgrades reported for Biote Corp. The company’s financial results remain a focal point for investors evaluating its performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.